Roy Taylor (scientist)

Sandoz Canada Launches PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin

Retrieved on: 
Friday, January 6, 2023
Research, Combination therapy, COVID-19, Diabetes, Trial of the century, Disease, Roy Taylor (scientist), Patient, Novartis, Exercise, Diet, Canada, Quality of life, Sale, Pharmaceutical industry

With the addition of these two products, Sandoz continues to support diabetic patients and strengthens its leadership position among generic companies in the diabetes therapeutic class products.

Key Points: 
  • With the addition of these two products, Sandoz continues to support diabetic patients and strengthens its leadership position among generic companies in the diabetes therapeutic class products.
  • BOUCHERVILLE, Quebec, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Today, Sandoz Canada announced the launch of PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin.
  • ® Registered trademark owned or used under licence by Sandoz Canada Inc.
  • This press release contains forward-looking statements, including, but not limited to, potential future revenues from the sale of PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin.

Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones

Retrieved on: 
Wednesday, December 21, 2022
Clinical trial, Fibrosis, Lipoprotein, EFX, Fatty liver disease, Cirrhosis, T2D, Therapy, Human, Histology, NASH, Patient, Safety, FDA, F4, Diabetes, Roy Taylor (scientist), Pharmaceutical industry, Medical imaging, Åkerö

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH), in patients with compensated cirrhosis fibrosis stage 4 (F4). Enrollment is also complete for the expansion cohort, known as Cohort D, evaluating EFX in combination with GLP-1 therapy in patients with fibrosis stage 1-3 (F1-F3) and Type 2 Diabetes Mellitus (T2D).

Key Points: 
  • “We look forward to reporting SYMMETRY data later next year as we evaluate EFX’s potential to slow or reverse progression of cirrhosis.”
    The Phase 2b SYMMETRY main study is a multicenter, randomized, double-blind, placebo-controlled, clinical trial in biopsy-confirmed NASH patients with compensated cirrhosis (F4, Child-Pugh class A).
  • One hundred eighty-two patients have been randomized to receive once-weekly subcutaneous dosing of 28mg EFX, 50mg EFX, or placebo.
  • To provide additional safety data from long-term follow up, patients will continue to receive EFX or placebo from 36 to 96 weeks.
  • Consistent with prior guidance, results from the Cohort D expansion cohort are expected in the second quarter of 2023, while results from the main study remain on track to be reported in the fourth quarter of 2023.

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

Retrieved on: 
Tuesday, December 6, 2022
Ministry of Food and Drug Safety, Patient, Sale, Ministry, Roy Taylor (scientist), Drug development, Daewoong Pharmaceutical, Quality of life, Multimedia, Metformin, Safety, SGLT2, Pharmaceutical industry, Food, Gemigliptin

Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.

Key Points: 
  • Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.
  • Daewoong Pharmaceutical, South Korea's leading healthcare company, became the first domestically to succeed in developing a new antidiabetic drug in this class by obtaining a product license.
  • Daewoong Pharmaceutical plans to actively pursue the global market through this product.
  • At the same time, the company has developed a roadmap to enter the global market over 10 countries including China, Brazil and Saudi Arabia by 2025 and 50 countries by 2030.

Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030

Retrieved on: 
Tuesday, December 6, 2022
Ministry of Food and Drug Safety, Patient, Sale, Ministry, Roy Taylor (scientist), Drug development, Daewoong Pharmaceutical, Quality of life, Metformin, Safety, SGLT2, Pharmaceutical industry, Food, Gemigliptin

Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.

Key Points: 
  • Until now, the development and approval of SGLT2 inhibitors have been carried out mainly by multinational pharmaceutical companies.
  • Daewoong Pharmaceutical, South Korea's leading healthcare company, became the first domestically to succeed in developing a new antidiabetic drug in this class by obtaining a product license.
  • Daewoong Pharmaceutical plans to actively pursue the global market through this product.
  • At the same time, the company has developed a roadmap to enter the global market over 10 countries including China, Brazil and Saudi Arabia by 2025 and 50 countries by 2030.

Base Healthcare Begins Its Mission to Raise Awareness of Testosterone Deficiency and Improve Patient Outcomes

Retrieved on: 
Friday, December 2, 2022
Prostate, Consumers United for Evidence-based Healthcare, Sleep, Bone density, Health, Weight gain, Cardiovascular disease, Incidence, Anxiety, Fatty liver disease, Scar, Exercise, Obesity, Depression, FDA, Roy Taylor (scientist), Testosterone, Body composition, Education, Blood pressure, Fatigue, Hypogonadism, Pharmaceutical industry, Medicine

Base Healthcare states that it is working to address low testosterone, or hypogonadism , in the United States because the condition currently affects approximately 39% of men 45 years and older.

Key Points: 
  • Base Healthcare states that it is working to address low testosterone, or hypogonadism , in the United States because the condition currently affects approximately 39% of men 45 years and older.
  • Base Healthcare's programs incorporate education on testosterone levels in America, including their decline since the 1970s due to the public's increasing stress levels and rates of obesity.
  • The services offered by Base Healthcare center around its patient engagement platform, whose dashboard allows members to monitor their improvement in the company's four pillars: sleep, stress, nutrition, and exercise.
  • Base Healthcare is a men's virtual health platform that focuses on foundational health and optimization using an FDA-approved oral testosterone therapy and patient-centered health coaching.

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

Retrieved on: 
Tuesday, November 29, 2022
Doctor of Philosophy, Hypoglycemia, MS, Insulin, Coronavirus Scientific Advisory Board (Turkey), Tel Aviv Sourasky Medical Center, Knowledge, Biotechnology, Roy Taylor (scientist), Patient, Randomness, Legislation, POD, T2DM, Glycated hemoglobin, Security (finance), Weight gain, Research, Metabolism, Metformin, TASE, Type 2 diabetes, Pressure, Safety, Pharmaceutical industry, Oramed, Obesity, MD, Diabetes

The trial met the primary endpoint of statistically significant reductions of HbA1c from baseline to Week 12.

Key Points: 
  • The trial met the primary endpoint of statistically significant reductions of HbA1c from baseline to Week 12.
  • "This paper presents interesting and important results of Oramed's Phase 2 dose ranging study of oral insulin.
  • Oramed Pharmaceuticals (Nasdaq: ORMP) (TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology.

Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

Retrieved on: 
Monday, November 21, 2022
SAN, VOC, POCT, Growth, RATS, Miniature pig, Mouse, Plasma protein binding, Feline coronavirus, Ciclosporin, Dog, Immunity, Therapy, Animal, Risk, Cat, Research, Saudi Research and Marketing Group, Cattle, Acceleration, US, EC50, Sale, Volatile organic compound, Market, Point-of-care testing, Roy Taylor (scientist), Guinea, Annual report, Subclinical infection, Horse, COVID-19, Human, AIMD, CAD, Prevalence, FCGS, Pharmaceutical industry, Vaccine, Pet, Ainos

SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has published preclinical data demonstrating the potential of its low-dose oral interferon-alpha (IFNα) formulation, VELDONA®, as treatment candidates for the two most common medical conditions for dogs and cats. The preclinical data can be accessed here.

Key Points: 
  • The Company initially applied VELDONA to feline coronavirus (FCoV)-infected fcwf-4 (feline microphage) systems to determine potency and dose translation.
  • Based on VELDONA's effective antiviral efficacy,the Company is planning an expansion of its use for the treatment of humans to treatment of animals.
  • Ainos is designing dose-finding field studies to identify optimal VELDONA dose via oromucosal administration for feline FCGS and canine CAD.
  • FCGS is a severe oral mucosal inflammatory disease afflicting cats, while CAD is an inflammatory skin disease found in dogs.

Memorial Hospital Pembroke achieves reaccreditation from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program®

Retrieved on: 
Tuesday, November 15, 2022
Quality, Health, Hospital, Accreditation, Fellowship of the Royal Colleges of Surgeons, Adult, Mortality, Obesity, Bariatric surgery, Systematic review, Memorial, Jose B. Lingad Memorial Regional Hospital, Citizens Memorial Healthcare, Leadership, Cardiovascular disease, JAMA, General surgery, Society, Memorial Hospital, Cancer, Center, Roy Taylor (scientist), Hypertension, Program, CDC, ACS, Patient, Disease, Metabolism, American College, Veni, vidi, vici, CEO, Meta-analysis, Surgeon, Memorial Hermann Health System, Patient safety, ASMBS, Patient satisfaction, Science, American College of Surgeons, Centers for Disease Control and Prevention, Medical device, Dentistry, Medicine, College

PEMBROKE PINES, Fla., Nov. 15, 2022 /PRNewswire-PRWeb/ -- When it comes to patients seeking surgical treatment for weight-loss and other metabolic conditions, healthcare experts recommend finding a nationally accredited bariatric center that meets the highest standards for patient safety and quality. South Florida patients don't need to go far as Memorial Hospital Pembroke recently received reaccreditation for this service by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP®), a joint Quality Program of the American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS).

Key Points: 
  • South Florida patients don't need to go far as Memorial Hospital Pembroke recently received reaccreditation for this service by the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP), a joint Quality Program of the American College of Surgeons (ACS) and the American Society for Metabolic and Bariatric Surgery (ASMBS).
  • Alongside Memorial Hospital Pembroke, there are two other bariatric centers part of Memorial Healthcare System that also hold this accreditation one at Memorial Regional Hospital in Hollywood and another at Memorial Hospital West in Pembroke Pines all three bariatric centers raising the standards of care high for the benefit of patients.
  • The MBSAQIP Standards, Optimal Resources for Metabolic and Bariatric Surgery, ensure that metabolic and bariatric patients receive multidisciplinary medical care, which improves patient outcomes and long-term success.
  • Memorial Hospital Pembroke's reaccreditation comes with a commitment to quality care that begins with expertly trained staff and the leadership of an experienced bariatric surgeon, who is Dr. Brett Cohen, Chief, Adult General Surgery and Bariatric Surgery Program.

Video: How Veterans' Needs Are Changing Healthcare Today

Retrieved on: 
Tuesday, November 8, 2022
Hodgkin lymphoma, VITAS, Agent Orange, Moral injury, Patient, Department, Population, Multiple myeloma, VITAS Healthcare, Hospice, Nursing, Korean War, Parkinson's disease, Baby boomers, Psychological trauma, Ageing, Vietnam War, B-cell lymphoma, District, Hospital, Gesture, Veteran, Leukemia, Roy Taylor (scientist), Multimedia, Greatest Generation, Cancer, United States Department of Veterans Affairs, General of the branch, Real estate, Health insurance, Medicine, United States Army, MD, WWII

MIAMI, Nov. 8, 2022 /PRNewswire/ -- Each day, US veterans from the Greatest Generation, those who battled in WWII, become a smaller subset of the living veteran population. Service members who fought in the Korean War and Vietnam War are now the largest veteran group requiring care as they near the end of life—and their needs vary significantly from the generation before. In a new video produced by VITAS® Healthcare, veteran clinicians and healthcare professionals describe the changing needs and how care must adapt to meet these needs.

Key Points: 
  • In a new video produced by VITAS Healthcare, veteran clinicians and healthcare professionals describe the changing needs and how care must adapt to meet these needs.
  • There are 5.6M Vietnam War veterans living today, many are nearing the end of life and with highly individualized needs.
  • The Department of Veterans Affairs currently projects that there are 5.6 million Vietnam War veterans living today.
  • Many of these veterans are nearing the end of life and with highly individualized needs.

ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®

Retrieved on: 
Thursday, November 3, 2022
Glucose, Private Securities Litigation Reform Act, Diet, Type 2 diabetes, Alloxan, Weight loss, SAN, CA, Obesity, PG, Risk, Industry, GLOBE, Vagotomy, SBIR, Ramakanta Panda, FDA, Safety, Metabolic disorder, Patient, Nasdaq, Plasma, Oxidative stress, Marketing, Roy Taylor (scientist), Research, Vagus nerve, Type 2, Anatomy, Collection, Annual report, U.S. Securities and Exchange Commission, Insulin, Stomach, Pancreas, Diabetes, Forward-looking statement, Reshaping Cultural Policies, CV, Liver, Technology, Security (finance), NIH, Hypoglycemia, SD, Insulin resistance, Ligation, Person, Miniature pig, Pharmaceutical industry, Medical device, T2DM

Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.

Key Points: 
  • Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.
  • Previously, the area under the curve of oral glucose tolerance tests (OGTTs) was calculated to quantify glycemic control.
  • The opportunity to present such compelling data on our proprietary DBSN device at this industry conference is a testament to the market potential of the technology to treat type 2 diabetes, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders.